Oncology drug launches face rising complexity from competition, regulation, and market dynamics. IQVIA highlights that only a fraction of launches meet forecasts, with access, differentiation, and stakeholder alignment as key hurdles. Success depends on mastering patient identification, pricing strategies, and engagement with oncologists, payers, and patients. The first six months are decisive, as early adoption shapes long-term trajectory. Companies must leverage real-world evidence, precision targeting, and flexible go-to-market models to build trust and value. Launch excellence now requires agility, cross-functional coordination, and patient-centric strategies to sustain growth in oncology’s evolving landscape.

Join for free to read